Immunogenicity, Reactogenicity of Shingrix in SLE

Inclusion Criteria: * Males or females ≥ 19 years of age at time of consent * ≥4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (13, 14) * Clinically stable SLE * Corticosteroid use: ≥ 5mg/day of prednisolone equivalent * Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks * Antimalarials (≤400 mg/day) * Azathioprine (≤3 mg/kg/day) * Mycophenolate mofetil (≤3 mg/day) * Tacrolimus (≤5mg/day) * Methotrexate (≤20mg/week) * Cyclosphosphamide (≤1mg/BSA/month) * Must understand and voluntarily sign an informed consent form including writing consent for data protection Exclusion Criteria: * Pregnant or lactating females * Acute infection with T \>38°C at the time of vaccination * Previous anaphylactic response to vaccine components or to egg * History of Guillain-Barre syndrome or demyelinating syndromes * Any condition including laboratory abnormality which places the subject at unacceptable risk * Subjects who decline to participate